what do i need to be an allergan injector
We're dedicated to advancing artful teaching and proud to be part of
Allergan Medical Establish®—an on-demand, personalized learning forum in medical aesthetics.
Allergan Medical Establish® helps you achieve desired patient outcomes by providing healthcare professionals with digital resources and training materials that tin add value to your practice.
Assets include prove-based, expert-led medical education that you can admission anytime, helping you lot advance your aesthetics knowledge, skills, and techniques.
Detect out more and join Allergan Medical Establish®.
New to
Allergan Aesthetics?
If you lot're interested in doing concern with
us, nosotros'd love to hear from you lot.
Please call united states of america at 1-844-NEW-2AGN.
REFERENCES: one. BOTOX® Cosmetic Prescribing Information, July 2020. 2. Dysport ® Prescribing Information, July 2020 3. Xeomin ® Prescribing Information, August 2020. 4. Jeuveau ® Prescribing Information, January 2020.
BOTOX Cosmetic (onabotulinumtoxinA) IMPORTANT SAFETY Data, INCLUDING BOXED WARNING See MORE +
BOTOX® Corrective (onabotulinumtoxinA) Important SAFETY Information, INCLUDING BOXED Alert
WARNING: DISTANT SPREAD OF TOXIN EFFECT
Postmarketing reports signal that the furnishings of BOTOX® Corrective and all botulinum toxin products may spread from the expanse of injection to produce symptoms consequent with botulinum toxin furnishings. These may include asthenia, generalized muscle weakness, diplopia, ptosis, dysphagia, dysphonia, dysarthria, urinary incontinence, and breathing difficulties. These symptoms have been reported hours to weeks after injection. Swallowing and breathing difficulties can be life threatening and there have been reports of death. The take chances of symptoms is probably greatest in children treated for spasticity, but symptoms tin can also occur in adults treated for spasticity and other weather condition, particularly in those patients who have an underlying condition that would predispose them to these symptoms. In unapproved uses and approved indications, cases of spread of effect have been reported at doses comparable to those used to treat cervical dystonia and spasticity and at lower doses.
Important Data
Indications
- BOTOX® Cosmetic (onabotulinumtoxinA) is indicated in adult patients for the temporary comeback in the appearance of:
- - Moderate to astringent glabellar lines associated with corrugator and/or procerus musculus action
- - Moderate to severe lateral canthal lines associated with orbicularis oculi action
- - Moderate to severe forehead lines associated with frontalis activity
IMPORTANT Rubber Information (continued)
CONTRAINDICATIONS
BOTOX® Cosmetic is contraindicated in the presence of infection at the proposed injection site(s) and in individuals with known hypersensitivity to whatsoever botulinum toxin preparation or to any of the components in the formulation.
WARNINGS AND PRECAUTIONS
Lack of Interchangeability Between Botulinum Toxin Products
The potency Units of BOTOX® Corrective are specific to the preparation and assay method utilized. They are not interchangeable with other preparations of botulinum toxin products and, therefore, units of biological activity of BOTOX® Cosmetic cannot exist compared to nor converted into units of whatsoever other botulinum toxin products assessed with any other specific analysis method.
Spread of Toxin Effect
Please refer to Boxed Warning for Afar Spread of Toxin Effect.
No definitive serious adverse event reports of distant spread of toxin effect associated with dermatologic use of BOTOX® Cosmetic at the labeled dose of 20 Units (for glabellar lines), 24 Units (for lateral canthal lines), 40 Units (for forehead lines with glabellar lines), 44 Units (for simultaneous handling of lateral canthal lines and glabellar lines), and 64 Units (for simultaneous treatment of lateral canthal lines, glabellar lines, and forehead lines) have been reported. Patients or caregivers should be advised to seek firsthand medical intendance if swallowing, speech communication, or respiratory disorders occur.
Serious Agin Reactions With Unapproved Use
Serious adverse reactions, including excessive weakness, dysphagia, and aspiration pneumonia, with some adverse reactions associated with fatal outcomes, have been reported in patients who received BOTOX® injections for unapproved uses. In these cases, the adverse reactions were non necessarily related to distant spread of toxin, but may take resulted from the administration of BOTOX® to the site of injection and/or next structures. In several of the cases, patients had pre-existing dysphagia or other significant disabilities. There is insufficient information to place factors associated with an increased risk for adverse reactions associated with the unapproved uses of BOTOX®. The safety and effectiveness of BOTOX® for unapproved uses take not been established.
Hypersensitivity Reactions
Serious and/or immediate hypersensitivity reactions take been reported. These reactions include anaphylaxis, serum sickness, urticaria, soft-tissue edema, and dyspnea. If such reactions occur, farther injection of BOTOX® Cosmetic should exist discontinued and appropriate medical therapy immediately instituted. 1 fatal example of anaphylaxis has been reported in which lidocaine was used as the diluent and, consequently, the causal agent cannot exist reliably determined.
Cardiovascular System
In that location have been reports following administration of BOTOX® of adverse events involving the cardiovascular system, including arrhythmia and myocardial infarction, some with fatal outcomes. Some of these patients had risk factors including pre-existing cardiovascular disease. Utilise caution when administering to patients with pre-existing cardiovascular disease.
Increased Adventure of Clinically Significant Effects With Pre-existing Neuromuscular Disorders
Individuals with peripheral motor neuropathic diseases, amyotrophic lateral sclerosis, or neuromuscular junction disorders (eg, myasthenia gravis or Lambert-Eaton syndrome) should be monitored when given botulinum toxin. Patients with neuromuscular disorders may be at increased risk of clinically significant effects including generalized musculus weakness, diplopia, ptosis, dysphonia, dysarthria, astringent dysphagia, and respiratory compromise from onabotulinumtoxinA (see Warnings and Precautions).
Dysphagia and Breathing Difficulties
Treatment with BOTOX® and other botulinum toxin products can upshot in swallowing or breathing difficulties. Patients with pre-existing swallowing or breathing difficulties may be more susceptible to these complications. In nearly cases, this is a upshot of weakening of muscles in the area of injection that are involved in breathing or oropharyngeal muscles that control swallowing or animate (see Boxed Warning).
Pre-existing Conditions at the Injection Site
Caution should be used when BOTOX® Cosmetic treatment is used in the presence of inflammation at the proposed injection site(southward) or when excessive weakness or cloudburst is present in the target musculus(s).
Dry Eye in Patients Treated With BOTOX® Cosmetic
There have been reports of dry centre associated with BOTOX® Corrective injection in or near the orbicularis oculi muscle. If symptoms of dry eye (eg, eye irritation, photophobia, or visual changes) persist, consider referring patients to an ophthalmologist.
Human Albumin and Manual of Viral Diseases
This product contains albumin, a derivative of homo blood. Based on effective donor screening and product manufacturing processes, it carries an extremely remote run a risk for transmission of viral diseases and variant Creutzfeldt-Jakob disease (vCJD). In that location is a theoretical risk for transmission of Creutzfeldt-Jakob disease (CJD), but if that run a risk actually exists, the risk of transmission would likewise be considered extremely remote. No cases of transmission of viral diseases, CJD or vCJD accept ever been identified for licensed albumin or albumin contained in other licensed products.
Adverse REACTIONS
The well-nigh frequently reported agin reactions following injection of BOTOX® Cosmetic for glabellar lines were eyelid ptosis (3%), facial pain (1%), facial paresis (one%), and muscular weakness (1%).
The most frequently reported adverse reaction post-obit injection of BOTOX® Cosmetic for lateral canthal lines was eyelid edema (1%).
The near frequently reported adverse reactions post-obit injection of BOTOX® Cosmetic for brow lines with glabellar lines were headache (nine%), brow ptosis (2%), and eyelid ptosis (two%).
DRUG INTERACTIONS
Co-administration of BOTOX® Cosmetic and aminoglycosides or other agents interfering with neuromuscular transmission (eg, curare-like compounds) should simply exist performed with caution as the effect of the toxin may exist potentiated. Use of anticholinergic drugs later administration of BOTOX® Cosmetic may potentiate systemic anticholinergic effects.
The consequence of administering different botulinum neurotoxin products at the same time or inside several months of each other is unknown. Excessive neuromuscular weakness may exist exacerbated by administration of another botulinum toxin prior to the resolution of the effects of a previously administered botulinum toxin.
Excessive weakness may also be exaggerated by assistants of a muscle relaxant before or after administration of BOTOX® Cosmetic.
Utilize IN SPECIFIC POPULATIONS
At that place are no studies or adequate information from postmarketing surveillance on the developmental adventure associated with utilise of BOTOX® Corrective in pregnant women. There are no information on the presence of BOTOX® Cosmetic in human or animal milk, the effects on the breastfed child, or the effects on milk production.
Please run across BOTOX® Cosmetic full Prescribing Information including Boxed Alert and Medication Guide.
dorsum to top -
BOTOX® Cosmetic (onabotulinumtoxinA) IMPORTANT Condom INFORMATION, INCLUDING BOXED WARNING
Alarm: Afar SPREAD OF TOXIN EFFECT
Postmarketing reports signal that the effects of BOTOX® Cosmetic and all botulinum toxin products may spread from the area of injection to produce symptoms consistent with botulinum toxin effects. These may include asthenia, generalized muscle weakness, diplopia, ptosis, dysphagia, dysphonia, dysarthria, urinary incontinence, and breathing difficulties. These symptoms have been reported hours to weeks after injection. Swallowing and breathing difficulties can exist life threatening and there have been reports of decease. The hazard of symptoms is probably greatest in children treated for spasticity, but symptoms tin besides occur in adults treated for spasticity and other atmospheric condition, specially in those patients who have an underlying condition that would predispose them to these symptoms. In unapproved uses and approved indications, cases of spread of outcome have been reported at doses comparable to those used to care for cervical dystonia and spasticity and at lower doses.
Important Information
Indications
- BOTOX® Corrective (onabotulinumtoxinA) is indicated in developed patients for the temporary improvement in the appearance of:
- - Moderate to severe glabellar lines associated with corrugator and/or procerus muscle activity
- - Moderate to severe lateral canthal lines associated with orbicularis oculi action
- - Moderate to severe forehead lines associated with frontalis activity
IMPORTANT SAFETY Data (continued)
CONTRAINDICATIONS
BOTOX® Corrective is contraindicated in the presence of infection at the proposed injection site(s) and in individuals with known hypersensitivity to any botulinum toxin preparation or to any of the components in the conception.
WARNINGS AND PRECAUTIONS
Lack of Interchangeability Between Botulinum Toxin Products
The potency Units of BOTOX® Cosmetic are specific to the preparation and analysis method utilized. They are non interchangeable with other preparations of botulinum toxin products and, therefore, units of biological activity of BOTOX® Corrective cannot be compared to nor converted into units of any other botulinum toxin products assessed with any other specific analysis method.
Spread of Toxin Effect
Please refer to Boxed Warning for Distant Spread of Toxin Result.
No definitive serious adverse event reports of distant spread of toxin effect associated with dermatologic use of BOTOX® Cosmetic at the labeled dose of 20 Units (for glabellar lines), 24 Units (for lateral canthal lines), 40 Units (for brow lines with glabellar lines), 44 Units (for simultaneous treatment of lateral canthal lines and glabellar lines), and 64 Units (for simultaneous treatment of lateral canthal lines, glabellar lines, and forehead lines) accept been reported. Patients or caregivers should be brash to seek immediate medical care if swallowing, speech communication, or respiratory disorders occur.
Serious Adverse Reactions With Unapproved Use
Serious adverse reactions, including excessive weakness, dysphagia, and aspiration pneumonia, with some agin reactions associated with fatal outcomes, take been reported in patients who received BOTOX® injections for unapproved uses. In these cases, the agin reactions were not necessarily related to distant spread of toxin, but may accept resulted from the administration of BOTOX® to the site of injection and/or adjacent structures. In several of the cases, patients had pre-existing dysphagia or other significant disabilities. There is insufficient information to identify factors associated with an increased risk for adverse reactions associated with the unapproved uses of BOTOX®. The rubber and effectiveness of BOTOX® for unapproved uses have not been established.
Hypersensitivity Reactions
Serious and/or immediate hypersensitivity reactions have been reported. These reactions include anaphylaxis, serum sickness, urticaria, soft-tissue edema, and dyspnea. If such reactions occur, farther injection of BOTOX® Corrective should be discontinued and appropriate medical therapy immediately instituted. One fatal case of anaphylaxis has been reported in which lidocaine was used as the diluent and, consequently, the causal amanuensis cannot exist reliably adamant.
Cardiovascular System
There take been reports post-obit administration of BOTOX® of agin events involving the cardiovascular organization, including arrhythmia and myocardial infarction, some with fatal outcomes. Some of these patients had risk factors including pre-existing cardiovascular disease. Use circumspection when administering to patients with pre-existing cardiovascular illness.
Increased Risk of Clinically Meaning Effects With Pre-existing Neuromuscular Disorders
Individuals with peripheral motor neuropathic diseases, amyotrophic lateral sclerosis, or neuromuscular junction disorders (eg, myasthenia gravis or Lambert-Eaton syndrome) should exist monitored when given botulinum toxin. Patients with neuromuscular disorders may exist at increased hazard of clinically significant effects including generalized muscle weakness, diplopia, ptosis, dysphonia, dysarthria, severe dysphagia, and respiratory compromise from onabotulinumtoxinA (see Warnings and Precautions).
Dysphagia and Breathing Difficulties
Handling with BOTOX® and other botulinum toxin products can event in swallowing or breathing difficulties. Patients with pre-existing swallowing or breathing difficulties may be more than susceptible to these complications. In most cases, this is a consequence of weakening of muscles in the area of injection that are involved in breathing or oropharyngeal muscles that control swallowing or breathing (run into Boxed Warning).
Pre-existing Conditions at the Injection Site
Caution should be used when BOTOX® Cosmetic treatment is used in the presence of inflammation at the proposed injection site(s) or when excessive weakness or atrophy is present in the target muscle(southward).
Dry Eye in Patients Treated With BOTOX® Cosmetic
There have been reports of dry eye associated with BOTOX® Cosmetic injection in or well-nigh the orbicularis oculi muscle. If symptoms of dry heart (eg, eye irritation, photophobia, or visual changes) persist, consider referring patients to an ophthalmologist.
Human Albumin and Transmission of Viral Diseases
This production contains albumin, a derivative of human blood. Based on effective donor screening and product manufacturing processes, it carries an extremely remote risk for transmission of viral diseases and variant Creutzfeldt-Jakob affliction (vCJD). There is a theoretical take chances for transmission of Creutzfeldt-Jakob illness (CJD), but if that risk actually exists, the chance of transmission would also be considered extremely remote. No cases of manual of viral diseases, CJD or vCJD have ever been identified for licensed albumin or albumin contained in other licensed products.
ADVERSE REACTIONS
The most oft reported adverse reactions following injection of BOTOX® Corrective for glabellar lines were eyelid ptosis (three%), facial pain (ane%), facial paresis (1%), and muscular weakness (1%).
The most ofttimes reported adverse reaction following injection of BOTOX® Corrective for lateral canthal lines was eyelid edema (1%).
The most oftentimes reported adverse reactions following injection of BOTOX® Corrective for forehead lines with glabellar lines were headache (ix%), forehead ptosis (2%), and eyelid ptosis (two%).
DRUG INTERACTIONS
Co-administration of BOTOX® Corrective and aminoglycosides or other agents interfering with neuromuscular manual (eg, curare-similar compounds) should only exist performed with caution every bit the effect of the toxin may exist potentiated. Use of anticholinergic drugs afterward administration of BOTOX® Cosmetic may potentiate systemic anticholinergic furnishings.
The event of administering unlike botulinum neurotoxin products at the aforementioned time or inside several months of each other is unknown. Excessive neuromuscular weakness may exist exacerbated by assistants of another botulinum toxin prior to the resolution of the effects of a previously administered botulinum toxin.
Excessive weakness may also be exaggerated by assistants of a muscle relaxant before or after administration of BOTOX® Cosmetic.
Utilize IN SPECIFIC POPULATIONS
In that location are no studies or adequate data from postmarketing surveillance on the developmental chance associated with use of BOTOX® Cosmetic in meaning women. There are no data on the presence of BOTOX® Corrective in human or beast milk, the effects on the breastfed child, or the effects on milk production.
Please see BOTOX® Corrective total Prescribing Information including Boxed Warning and Medication Guide.
mcmullenherat1941.blogspot.com
Source: https://hcp.botoxcosmetic.com/training
Post a Comment for "what do i need to be an allergan injector"